ĐẶC ĐIỂM LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ CO THẮT NỬA MẶT BẰNG TIÊM BOTULINUM TOXIN A

Abstract

Background: Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Although benign, HFS can cause functional disability due to its impact on social interaction and excessive blinking that impairs vision. The most effective therapy reported for HFS is low-dose botulinum toxin (BoNT) injection into the facial muscles. Objectives: To evaluate the treatment effectiveness of Bobotulinum toxin A in the treatment Hemifacial spasm at Soc Trang General Hospital in 2024. Materials and methods: A case series of 30 patients with hemifacial spasm from July 21, 2023. All patients received injections of Botulinum toxin A (Dysport). Results: The mean effective duration was 11.4 ± 2.02 (week). The treatment response after Abobotulinum toxin A injection gradually increased from week 3 to week 8 (from 93.3% to 96.7%). At week 12, 100% of patients no longer showed treatment response. Adverse events included local hematoma at the injection site in 3.3% of patient and asymmetric eye size in 3.3% of patient. Conclusion: Injection of AbobotulinumtoxinA for hemifacial spasm achieves high clinical efficacy and safety. The therapy significantly improves spasms with a mean duration of effect of 11,4 ± 2,02 weeks, with no serious adverse events recorded.